JHS Svendgaard Laboratories Ltd (JHS)

Fast Moving Consumer Goods · FMCG · NSE · Updated 2 September 2026

By StockFin Research Team • AI-Assisted Analysis • Source: BSE/NSE Filings

₹7.83 ↓ 33.42% (1Y)

🎯 Key Takeaways

JHS Svendgaard Laboratories Ltd appears to be in a turnaround phase, marked by persistent losses, negative ROE and ROCE, and declining share price performance over the past year. Despite stable promoter holding, the company is navigating financial stress with minimal institutional interest and volatile quarterly profitability.
Revenue declined 7.1% QoQ to ₹30 in Q1FY27.
⚠️ 1) Persistent negative profitability metrics (ROE, ROCE) and volatile quarterly earnings raise concerns about operational sustainability. 2) The compa

Market Cap

₹68

P/B Ratio

0.40

ROE

-1.1%

ROCE

-1.1%

Debt/Equity

0.03

Promoter

33.9%

✨ Ask AI About JHS 📊 Interactive Charts

📖 The Story

JHS Svendgaard Laboratories Ltd appears to be in a turnaround phase, marked by persistent losses, negative ROE and ROCE, and declining share price performance over the past year. Despite stable promoter holding, the company is navigating financial stress with minimal institutional interest and volatile quarterly profitability. Management is actively restructuring capital allocation and seeking shareholder approval for greater flexibility in fund utilization, suggesting a strategic pivot to stabilize operations and restore profitability.

📰 What's Happening

In Q1FY27, JHS disclosed that its board approved a variation in the utilization of proceeds from its 2021 preferential issue, extending timelines to March 31, 2027 and broadening permissible uses to include business expansion and strategic initiatives. Shareholders are currently voting via postal ballot on this modification, with voting open from June 30 to July 29, 2026. The reallocation includes ₹599.99 lakhs for equipment, ₹1,650 lakhs for group entity fund infusion, and ₹750 lakhs for general corporate purposes. Additionally, the trading window for insiders closed on July 1, 2026, ahead of the un-audited quarterly results for June 30, 2026, indicating upcoming financial disclosure.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	22	23	33	30
Operating Profit	-1	-0	-3	0
OPM %	-4.3%	-1.0%	-10.6%	0.9%
Net Profit	-0	1	-4	1
EPS	₹-0.02	₹0.09	₹-0.42	₹0.12

The company’s quarterly performance shows mixed but slightly improving trends: revenue rose to ₹30 lakhs in June 2026 from ₹22 lakhs in September 2025, and net profit turned positive at ₹1 lakh after two consecutive quarters of loss. However, operating performance remains fragile, with operating profit of ₹0 in June 2026 and a loss of ₹3 lakhs in March 2026. Margins remain thin and volatile, reflecting ongoing operational challenges. The sequential improvement in revenue and return to profitability in the latest quarter may signal early stabilization, though profitability is not yet sustainable.

🔮 Management Outlook & What's Next

Management has not provided explicit forward guidance in the reviewed filings, but the board’s approval of a modified fund utilization plan indicates a strategic shift toward reinvestment and operational expansion. The extension of the fund deployment timeline to March 2027 and the emphasis on business expansion suggest management is focused on scaling operations and improving margins. The upcoming quarterly results and shareholder vote on fund reallocation are key near-term catalysts that may clarify management’s near-term priorities and investment outlook.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

Item	Mar 2025	Mar 2025	Mar 2026	Mar 2026
Equity Capital	86	86	86	87
Reserves	96	85	88	87
Borrowings	4	5	11	15
Total Liabilities	208	201	207	215
Fixed Assets	87	90	85	87
Investments	4	4	5	5
Total Assets	208	201	207	215

The balance sheet shows a stable equity base of approximately ₹86–87 crores with modest growth in reserves, while borrowings remain very low at ₹11–15 lakhs, indicating minimal leverage. Total assets have gradually increased to ₹215 lakhs as of March 2026, reflecting asset accumulation without significant debt-funded expansion. This suggests a conservative capital structure and limited external financing reliance, with growth likely funded internally or through restricted fund allocations under the preferential issue.

💰 Cash Flow Statement (₹ Cr)

Item	Mar 2025
Operating	-5
Investing	-20
Financing	+23
Net Cash Flow	-2

👥 Shareholding Pattern

Category	Q3FY26	Q4FY26	Q1FY27
Promoters	34.6%	33.9%	33.9%
FII	1.6%	3.6%	3.1%
DII	0.0%	0.0%	0.0%
Public	47.6%	46.6%	47.5%
# Shareholders	25,151	25,330	25,150

Promoter holding has remained steady at around 33.85% in recent quarters, indicating no dilution or sale pressure. Institutional ownership (FII) is very low at 3.14% in Q1FY27, down from 3.6% in Q4FY26, while DII holding is zero, suggesting limited investor interest. The broad public shareholder base (47.48%) and high number of shareholders (25,150) indicate retail dominance. There are no signs of institutional accumulation, and the low float may contribute to share price volatility.

⚖️ Peer Comparison — FMCG

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
HINDUNILVR	4.69 L Cr	31.3	29.8%	30.7%	0.00
ITC	3.34 L Cr	16.8	36.0%	27.8%	0.03
NESTLEIND	2.78 L Cr	73.0	99.2%	73.9%	0.00
VBL	1.37 L Cr	40.6	21.5%	17.4%	0.10
BRITANNIA	1.25 L Cr	47.9	54.1%	51.1%	0.27
LENSKART	1.15 L Cr	173.3	11.9%	7.7%	0.03
MARICO	1.09 L Cr	57.3	54.2%	46.4%	0.08
TATACONSUM	1.02 L Cr	62.2	10.2%	8.0%	0.10
GODREJCP	92,112	48.1	17.8%	15.1%	0.33
DABUR	68,173	34.6	21.3%	17.1%	0.09

🔗 Peer Stock Analyses

HINDUNILVR ITC NESTLEIND VBL BRITANNIA

⚠️ Risk Factors

1) Persistent negative profitability metrics (ROE, ROCE) and volatile quarterly earnings raise concerns about operational sustainability. 2) The company’s ability to deploy preferential issue funds as planned is critical but subject to shareholder approval and execution risks. 3) Low institutional interest and thin trading may lead to high volatility and limited liquidity. 4) Management’s strategic pivot lacks clear disclosure of timelines or expected returns, increasing execution uncertainty.

📋 Recent Filings

🧠 Analyst's Read

JHS Svendgaard Laboratories is in a critical phase of strategic repositioning, with management seeking shareholder approval to reconfigure fund usage and extend timelines for deployment. The latest quarter shows early signs of revenue recovery, but profitability remains fragile. Investors should monitor the outcome of the postal ballot vote, the upcoming quarterly results, and any commentary on margin improvement or capital allocation priorities in the next earnings cycle.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on JHS

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-02.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JHS files new disclosures

Track JHS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track JHS — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd